Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Stockholders' Equity

v3.20.1
Condensed Statements of Stockholders' Equity - USD ($)
Class A Preferred Stock
Class A Common Shares
Common Shares
Common Stock Issuable
Additional Paid-in Capital
Accumulated Deficit
Total
Balances at Dec. 31, 2018 $ 0 $ 0 $ 3,000 $ 2,085,000 $ 113,378,000 $ (79,070,000) $ 36,396,000
Balances (in shares) at Dec. 31, 2018 250,000 1,000,000 26,610,183        
Issuance of common shares - Founders Agreement $ 0 $ 0 $ 0 (2,085,000) 2,085,000 0 0
Issuance of common shares - Founders Agreement (in shares) 0 0 709,314        
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech $ 0 $ 0 $ 0 0 375,000 0 375,000
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech (in shares) 0 0 108,069        
Issuance of warrants - Horizon Notes $ 0 $ 0 $ 0 0 888,000 0 888,000
Issuance of warrants - Horizon Notes (in shares) 0 0 0        
Stock-based compensation expenses $ 0 $ 0 $ 0 0 432,000 0 432,000
Stock-based compensation expenses (in shares) 0 0 76,000        
Exercise of warrants $ 0 $ 0 $ 0 0 0 0 0
Exercise of warrants (in shares) 0 0 57,867        
Net loss $ 0 $ 0 $ 0 0 0 (9,613,000) (9,613,000)
Balances at Mar. 31, 2019 $ 0 $ 0 $ 3,000 0 117,158,000 (88,683,000) 28,478,000
Balances (in shares) at Mar. 31, 2019 250,000 1,000,000 27,561,433        
Balances at Dec. 31, 2019 $ 0 $ 0 $ 4,000 4,923,000 172,184,000 (125,459,000) 51,652,000
Balances (in shares) at Dec. 31, 2019 250,000 845,385 39,403,519        
Issuance of common shares - Founders Agreement $ 0 $ 0 $ 0 (4,923,000) 4,923,000 0 0
Issuance of common shares - Founders Agreement (in shares) 0 0 1,206,667        
Issuance of common shares, net of offering costs - At-the-Market Offering $ 0 $ 0 $ 0 0 4,910,000 0 4,910,000
Issuance of common shares, net of offering costs - At-the-Market Offering (in Shares) 0 0 1,248,834        
Issuance of common shares - Equity fee on At-the-Market Offering $ 0 $ 0 $ 0 0 125,000 0 125,000
Issuance of common shares - Equity fee on At-the-Market Offering (in shares) 0 0 31,220        
Issuance of common shares under ESPP $ 0 $ 0 0 169,000 0 $ 169,000
Issuance of common shares under ESPP (in shares)   68,351       68,351
Stock-based compensation expenses $ 0 $ 0 $ 0 0 805,000 0 $ 805,000
Stock-based compensation expenses (in shares) 0 0 115,250        
Exercise of warrants $ 0 $ 0 $ 0 0 0 0 0
Exercise of warrants (in shares) 0 0 2,999        
Net loss $ 0 $ 0 $ 0 0 0 (11,857,000) (11,857,000)
Balances at Mar. 31, 2020 $ 0 $ 0 $ 4,000 $ 0 $ 183,116,000 $ (137,316,000) $ 45,804,000
Balances (in shares) at Mar. 31, 2020 250,000 845,385 42,076,840